This AIM presentation was given at the Centers for Disease Control and Prevention (CDC) 2024 National Immunization Conference (NIC) on the barriers and successes to enrolling birthing institutions in the Vaccines for Children (VFC) program. AIM conducted roundtables and key informant interviews with immunization program (IP) managers and partner organizations in spring 2023 to identify barriers and successes in enrolling birthing institutions in the VFC program and implementing new birth dose immunization products. Using these findings, AIM supported IPs in implementing nirsevimab after the official August 2023 recommendation from the Advisory Committee on Immunization Practices (ACIP). Throughout the 2023-2024 RSV season, AIM followed jurisdictional IP activities to implement nirsevimab and related emerging challenges. AIM plans to support members in implementing lessons learned from the 2023-2024 season in planning for the upcoming RSV season. AIM shared insights gained from roundtables, key informant interviews, and tracking VFC enrollment of birthing institutions during the 2023-2024 RSV season and offered guidance for future enrollment strategies.
Details
- Format: Oral presentation
- Event: National Immunization Conference (NIC) 2024
- Authors:
- Michelle Fiscus, MD, FAAP (Presenter)
- Katelyn Wells, PhD
- Emily Less, MPH
- Related Resources: